Indivior Pharmaceuticals (FRA:E7P) Stock Based Compensation: €28 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:E7P Indivior Pharmaceuticals Inc FRA:E7P
71 GF Score
Price €32.80
GF Value €21.12
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Stock Based Compensation?

Indivior Pharmaceuticals FRA:E7P -1.20% 71 Stock Based Compensation is €28 Mil as of Jun. 2026. GuruFocus rates FRA:E7P with a GF Score™ of 71/100 and a GF Value™ of €21.12 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Indivior Pharmaceuticals's Stock Based Compensation for the three months ended in Jun. 2026 was €10 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was €28 Mil.

Indivior Pharmaceuticals Stock Based Compensation Related Terms

Indivior Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Stock Based Compensation Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.74 15.10 20.17 22.92 22.20

Indivior Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.94 5.96 4.27 7.79 9.55
FRA:E7P
71GF Score
Indivior Pharmaceuticals Inc FRA:E7P
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indivior Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €28 Mil.

What does a Stock Based Compensation of €28 Mil mean?
Indivior Pharmaceuticals (FRA:E7P) has a Stock Based Compensation of €28 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Indivior Pharmaceuticals and its competitors.
Is Indivior Pharmaceuticals' Stock Based Compensation too high?
Indivior Pharmaceuticals' current Stock Based Compensation is €28 Mil. Overall, Indivior Pharmaceuticals has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Stock Based Compensation compare to KNSA and AMRX?
Indivior Pharmaceuticals' Stock Based Compensation of €28 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current Stock Based Compensation is €28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (FRA:E7P) is currently considered Significantly Overvalued. The stock's GF Value™ is €21.12, compared to a current price of €32.80 — trading 55.3% above its estimated fair value. The current Stock Based Compensation is €28 Mil. Indivior Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Indivior Pharmaceuticals (FRA:E7P), the current Stock Based Compensation is €28 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (FRA:E7P) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of €32.80 is trading 55.3% above its estimated GF Value™ of €21.12. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:E7P:

  • Stock Based Compensation: €28 Mil
  • GF Value™: €21.12 vs. price of €32.80 (55.3% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the FRA:E7P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges INDV:USA
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
71GF Score

Get the complete analysis for FRA:E7P

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.80
Price
€21.12
GF Value